• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Avatrombopag Maleate
BioHub® Magnetic Separator
Avatrombopag
Ursodeoxycholic acid
Troxerutin
CytoLinX® BRTF Single-use Top-driven Bioreactor Bag

M&As this week: Sun Moral International (HK), Immuno Holding

pharmaceutical-technologyMarch 27, 2017

Tag: immuno , M&As

Sun Moral International (HK), a subsidiary of Chinese pharmaceutical company Sihuan Pharmaceutical Holdings Group, has acquired the entire equity interest in Ambest Pharmaceutical (China) Company.

"Immuno Holding’s subsidiary 1111267 B.C has reached an agreement to acquire Immunotec."

The target company is a manufacturer of large-volume injections and was acquired for a consideration of ¥1.1bn ($159.47m).

Immuno Holding’s subsidiary 1111267 B.C has reached an agreement to acquire Immunotec.

The purchase consideration for the acquisition is $0.485 a share.

Based in Canada, the target company develops, manufactures and sells nutritional products.

Previous:Cancer Research UK to support Precision Panc project for pancreatic cancer

Next:Biomedical Institute for Global Health Research and Technology (BIGHEART) at NUS and Holmusk Partner

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

M&As this week: Sun Moral International (HK), Immuno Holding | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Human Immunoglobulin (pH4) for Intravenous Injection* Hualan

Human Immunoglobulin (pH4) for Intravenous Injection* Hualan
hualan human tetanus immunoglobulin

hualan human tetanus immunoglobulin
ITP Human Immunoglobulin (pH4) for Intravenous Injection

ITP Human Immunoglobulin (pH4) for Intravenous Injection
Hualan's Human Rabies Immunoglobulin

Hualan's Human Rabies Immunoglobulin
Hualan bio Human Hepatitis B Immunoglobulin

Hualan bio Human Hepatitis B Immunoglobulin
Human Rabies Immunoglobulin

Human Rabies Immunoglobulin
Human Rabies Immunoglobulin of Hualan Bio

Human Rabies Immunoglobulin of Hualan Bio
hualan-human tetanus immunoglobulin

hualan-human tetanus immunoglobulin
Hualan good immunogenicity performance Influenza Vaccine

Hualan good immunogenicity performance Influenza Vaccine
Tetanus toxin immunoglobulin

Tetanus toxin immunoglobulin

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service